Literature DB >> 25462240

Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands.

Marion Donnier-Maréchal1, Paul-Emmanuel Larchanché2, Delphine Le Broc3, Christophe Furman4, Pascal Carato5, Patricia Melnyk6.   

Abstract

Sigma 1 receptors are associated with neurodegenerative and psychiatric disorders. These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents. The involvement of these receptors has also been observed in neuropathic pain and cancer. Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clinical trials. Thus the development of sigma 1 ligands is of interest to a new generation of drugs. Previous work in our lab underlined the potency of benzannulated bicyclic compounds as interesting ligands. Herein the work was extended to a series of novel tricyclic compounds. Carboline- and phenothiazine-derivated compounds were designed and synthesized. In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (Ki = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Carboline; Phenothiazine; Phenoxazine; Sigma receptors; Tetrahydrobenzofuropyridine

Mesh:

Substances:

Year:  2014        PMID: 25462240     DOI: 10.1016/j.ejmech.2014.10.053

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Synthesis and structure-activity relationship studies of novel 3,9-substituted α-carboline derivatives with high cytotoxic activity against colorectal cancer cells.

Authors:  Yi-Chien Lin; Yi-Fong Chen; Li-Shin Tseng; Yueh-Hsuan Lee; Susan L Morris-Natschke; Sheng-Chu Kuo; Ning-Sun Yang; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Eur J Med Chem       Date:  2016-01-07       Impact factor: 6.514

Review 2.  Endocannabinoid control of glutamate NMDA receptors: the therapeutic potential and consequences of dysfunction.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Manuel Merlos; Javier Garzón-Niño
Journal:  Oncotarget       Date:  2016-08-23

3.  Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Javier Garzón
Journal:  Oncotarget       Date:  2018-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.